ERBB2 and breast carcinoma: On the other hand, patients with HER2+ breast cancer had higher serum miR-10b median levels than patients with HER2− breast cancer (0.59 vs. 0.32, p = 0.0004) and HDs (0.59 vs. 0.36, p = 0.0002) (Figure 2B).